Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moExternal Resources
HYDROXYCHLOROQUINE SULFATE by Novartis is 4-aminoquinoline antimalarial [see ] and antirheumatic agent. Approved for acute, chronic rheumatoid arthritis in adults, systemic lupus erythematosus in adults and 4 more indications. First approved in 1995.
Drug data last refreshed 20h ago
4-aminoquinoline antimalarial [see ] and antirheumatic agent. Rheumatoid Arthritis, Systemic Lupus Erythematosus and Chronic Discoid Lupus Erythematosus The mechanisms underlying the anti-inflammatory and immunomodulatory effects of hydroxychloroquine sulfate in the treatment of rheumatoid…
Worked on HYDROXYCHLOROQUINE SULFATE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion
To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo